Jian Jin

This inventor holds 20 USPTO granted patents and 28 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Cancer Treatment Compounds. Top assignees: Icahn School of Medicine at Mount Sinai, The University of North Carolina at Chapel Hill, Glaxo Group Limited. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jian Jin. Retrieved from https://idiyas.com/inventor/jian-jin-s5ndqk71

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 28)

% Patents Active = 70.0

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 8 (Patent Applications = 13)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 22(Granted Patents)

Location History:

Chapel Hill, NC (US) (2015)
Collegeville, PA (US) (2011 - 2023)
New York, NY (US) (2022 - 2024)

Company Filing History:

8 out of 538

Icahn School of Medicine at Mount Sinai

patents

6 out of 1,329

The University of North Carolina at Chapel Hill

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Protein Tyrosine Kinase

EZH2

WDR5

MEK

CDK4/6

Prolyl Hydroxylase

Heterobifunctional Compounds

Epigenetic Modifiers

M1 Receptor

Beta-Glucuronidase Inhibitors

Mitogen-Activated Protein Kinase

Cancer Therapy

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12678507 - Protein tyrosine kinase 6 (PTK6) degradation / disruption compounds and methods of use (2026-07-14),

2. 12465648 - Heterobifunctional compounds as degraders of HPK1 (2025-11-11),

3. 12274697 - Compositions and methods for treating EZH2-mediated cancer (2025-04-14),

4. 12110295 - WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use (2024-10-08),

5. 12103924 - Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use (2024-10-01),

6. 11905537 - Bifunction chemical epigenetic modifiers and methods of use (2024-02-20),

7. 11643397 - Prolyl hydroxylase inhibitors (2023-05-09),

8. 11541051 - Compositions and methods for treating CDK4/6-mediated cancer (2023-01-03),

9. 11510920 - Compositions and methods for treating EZH2-mediated cancer (2022-11-29),

10. 11472799 - Serine threonine kinase (AKT) degradation / disruption compounds and methods of use (2022-10-18),

11. 11339178 - Inhibitors of microbial beta-glucuronidase enzymes and uses thereof (2022-05-24),

12. 11278550 - Compositions and methods for the treatment of Prader-Willi syndrome (2022-03-22),

13. 11254654 - Heterochromatin gene repression inhibitors (2022-02-22),

14. 9156822 - [object Object] (2015-10-13),

15. 8481566 - Compounds which have activity at M1 receptor and their uses in medicine (2013-07-09),

Title: The Innovative Mind of Jian Jin: Pioneering Patents in Biomedicine

Introduction

Jian Jin is a distinguished inventor based in New York, NY, recognized for his significant contributions to the field of biomedicine. With a remarkable portfolio of 10 patents, he has made strides in developing innovative compounds aimed at treating various WDR5-mediated diseases and other conditions.

Latest Patents

Among his latest innovations is the patent focusing on WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use. This patent outlines the creation of WDR5 ligands, degradation/disruption tags, and linkers that play a crucial role in the treatment of specific diseases linked to WDR5. Another notable patent involves mitogen-activated protein kinase kinase (MEK) degradation compounds. This disclosure emphasizes heterobifunctional compounds, which include bi-functional small molecule compounds, and details their application for treating diseases, showcasing inventive methods for identifying such compounds.

Career Highlights

Jian Jin has built an impressive career, holding key positions at prestigious institutions such as the University of North Carolina at Chapel Hill and the Icahn School of Medicine at Mount Sinai. His work at these renowned establishments has significantly contributed to the development and refinement of his innovative compounds, further establishing his standing in the field.

Collaborations

Throughout his career, Jian Jin has collaborated with notable experts in his field, including Bryan Leo Roth and Stephen Frye. These partnerships have fostered an environment of innovation and have facilitated the sharing of knowledge and expertise, propelling his research endeavors forward.

Conclusion

Jian Jin's legacy as an inventor is marked by his unparalleled contributions to biomedicine and his dedication to advancing therapeutic treatments. His patents not only reflect a deep understanding of complex biological mechanisms but also underscore his commitment to improving patient outcomes through innovation. As he continues to explore uncharted territories in biomedical research, Jian Jin remains a vital figure in the landscape of modern medical advancements.

Profile summary based on public USPTO records.